Off-label Use of Dupilumab for Pediatric Patients with Atopic Dermatitis: A Multicenter Retrospective Review

Treatment for children with moderate-severe atopic dermatitis is a significant unmet need; dupilumab is currently licensed only for patients over age 11.Off-label access to dupilumab is achievable, and shows similar treatment success rates and tolerability as in adult patients, but optimal pediatric dosing has not been defined..

Source: Journal of the American Academy of Dermatology - October 9, 2019 Category: Dermatology Authors: Sean Igelman, Anastasia O. Kurta, Umar Sheikh, Ashley McWilliams, Eric Armbrecht, Stephanie R. Jackson Cullison, Douglas W. Kress, Anna Smith, Leslie Castelo-Soccio, James Treat, William D. Boothe, Lucia Z. Diaz, Moise L. Levy, Avni Patel, Lara Wine Lee, Source Type: research